Saturday 17 October 2026 Export WHWK’s income statement to Excel — free account

Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024. In the quarter to June 2026, revenue grew 33.5%, EPS grew 73.7% and free cash flow grew 72.6%, each against the same quarter a year earlier.

2.89 0.15 −4.93%

Follow WHWK

Alert me

Market cap: $173.3M
P/E: 0.0×
Fwd P/E: −3.2×
Dividend yield: —
F-score: 4/9
Altman Z: 1.52
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.58

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	3	6	—	—	—	—	—	—

Insider Ownership 60.36%

Capital & Financial Ratios $m

Market Cap 173.31

Revenue 27.78

Net Income (79.83)

Free Cash Flow (69.35)

Net Debt (189.98)

Current Ratio 17.38

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.18)

P/S ratio 8.65

P/B ratio 1.31

Past 5Y EPS Growth —

This Y EPS Growth (187.12%)

Next Y EPS Growth 5.67%

Next Y revenue growth (115.75%)

Next 5Y EPS Growth 18.93%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 63.36%

10-year low 10-year high

P/B against its own 10 years 57.02%

10-year low 10-year high

EV/Sales against its own 10 years 34.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	109	47	146	190
Receivables	5	6	—	—
Inventory	6	5	—	—
Other	—	3	3	—
	125	61	149	192

	2023	2024	2025	Q'26
Payables	6	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	26	17	15	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	(13.29%)	(22.27%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	(4.88%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	7	—	—	—	7
’24	5	6	7	7	26
’23	6	6	6	6	24
’22	2	3	4	5	15
’21	0	—	—	1	1
’20	—	15	0	(1)	15

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(15)	—	—	—
’25	(12)	(53)	(15)	(17)	(97)
’24	(20)	(9)	(16)	(15)	(60)
’23	(21)	(17)	(12)	(10)	(60)
’22	(19)	(11)	(8)	(11)	(50)
’21	11	(3)	(17)	(12)	(22)
’20	(4)	10	(16)	(3)	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(15)	—	—	—
’25	(12)	(53)	(15)	(17)	(98)
’24	(20)	(10)	(16)	(15)	(61)
’23	(23)	(17)	(13)	(10)	(64)
’22	(19)	(11)	(8)	(11)	(50)
’21	11	(3)	(17)	(12)	(22)
’20	(4)	10	(16)	(3)	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	(0.20)	—	—	—
’25	1.83	(0.76)	(0.26)	(0.34)	(0.33)
’24	(0.68)	(0.54)	(0.46)	(0.67)	(2.36)
’23	(0.57)	(0.67)	(0.60)	(0.60)	(2.44)
’22	(0.66)	(0.87)	(0.68)	(0.52)	(2.69)
’21	(2.15)	(0.60)	(9.17)	(0.77)	(12.41)
’20	(1.50)	3.45	(1.14)	(1.50)	(1.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	23.40	6.75	6.30	14.31	11.00	1.90	1.21	1.39	Analyst estimates 2026–2028 Powerpack
	High	—	—	78.00	63.75	34.65	49.80	25.36	13.45	3.60	3.81
People
People	Employees	—	25	27	11	12	39	79	89	40	23
	Revenue/emp, $m	—	0.00	0.75	0.00	1.22	0.03	0.19	0.27	0.65	0.31
Income, $m
Income, $m	Revenue	—	—	20	—	15	1	15	24	26	7
	Gross margin, %	0.00	0.00	100.00	0.00	100.00	100.00	91.23	88.47	88.36	89.36
	EBT	(17)	(21)	(10)	(23)	(3)	(110)	(61)	(66)	(64)	(21)
	EBT margin, %	0.00	0.00	(51.58)	0.00	(23.84)	(9,829.29)	(397.69)	(270.04)	(245.13)	(288.26)
	Net income	(17)	(21)	(10)	(23)	(3)	(110)	(61)	(66)	(64)	(21)
	Depreciation	0	0	0	0	0	74	3	(3)	(1)	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	8.91	0.00	5.74	0.13	0.68	0.90	0.96	0.12
	Earnings	(298.51)	(14.80)	(4.65)	(8.55)	(1.50)	(12.41)	(2.69)	(2.44)	(2.36)	(0.33)
	Cash flow	(276.24)	(13.06)	(2.57)	(8.81)	(5.00)	(2.51)	(2.21)	(2.22)	(2.20)	(1.57)
	Capex	(1.99)	(0.01)	(0.02)	(0.09)	(0.01)	(0.01)	(0.02)	(0.15)	(0.06)	(0.01)
	Free cash flow	(278.23)	(13.07)	(2.58)	(8.90)	(5.00)	(2.52)	(2.22)	(2.36)	(2.26)	(1.58)
	Book value	(1,515.27)	12.06	25.92	13.50	(4.89)	15.29	7.04	3.91	1.94	2.20
	Shares, m	0	1	2	3	3	9	23	27	27	62
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	0.00	0.00	0.00	0.00	0.00	5.04
	P/S	—	—	0.00	—	2.56	307.88	18.21	2.27	3.29	5.39
	P/B	—	—	0.98	—	0.00	1.58	1.75	0.52	1.63	1.10
	EV/Sales	—	—	0.00	—	2.33	96.61	6.94	(2.16)	1.51	0.19
	EV/FCF	—	—	0.84	—	(2.67)	(3.00)	(2.11)	0.83	(0.64)	(0.05)
Cash, $m
Cash, $m	Operating cash flow	(16)	(19)	(6)	(24)	(13)	(22)	(50)	(60)	(60)	(97)
	Capex	0	0	0	0	0	0	0	(4)	(2)	(1)
	Free cash flow	(16)	(19)	(6)	(24)	(13)	(22)	(50)	(64)	(61)	(98)
Balance, $m
Balance, $m	Working capital	(13)	17	59	36	(11)	136	161	98	44	134
	Total debt	12	—	—	0	1	—	—	—	—	—
	Net debt	(2)	(20)	(63)	(38)	(3)	(149)	(173)	(109)	(47)	(146)
	Shareholders’ equity	(86)	17	59	37	(12)	136	158	105	52	136
Returns, %
Returns, %	ROA	(1,731.56)	(190.77)	(24.42)	(44.73)	(15.20)	(125.31)	(35.37)	(41.54)	(62.83)	(18.63)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(804.45)	0.00
	ROE	48.40	64.97	(27.32)	(48.89)	(37.05)	(178.65)	(41.06)	(49.90)	(80.79)	(21.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
PEPG PepGen, Inc.	$175.2M	— (loss-making)	—	—	n/m	+33.02% (above 0%: growing)	0.00%	0.00%	Compare
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%	Compare
WHWK Whitehawk Therapeutics, Inc.	$173.3M	— (loss-making)	— (loss-making)	+33.48% (above 0%: growing)	n/m	+72.57% (above 0%: growing)	89.36%	0.00%
DTIL Precision BioSciences, Inc.	$170.3M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	+33.73% (above 0%: growing)	100.00%	0.00%	Compare
CHRS Coherus Oncology, Inc.	$165.3M	— (loss-making)	— (loss-making)	+39.53% (above 0%: growing)	n/m	−33.15% (below 0%: shrinking)	70.35%	(225.98%)	Compare
IPHA Innate Pharma S.A. Sponsored ADR	$165.3M	— (loss-making)	—	+246.29% (above 0%: growing)	+106.08% (above 0%: growing)	−929.03% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$174.5M	—	—	+219.78%	—	+1.97%	35.50%	0.00%

All 614 Biotechnology stocks →

Whitehawk Therapeutics, Inc. (WHWK) key facts

Concern: Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024.
Whitehawk Therapeutics, Inc. (WHWK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, WHWK traded at $2.89, a market capitalization of $173.3 million.
Return on equity was −21.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.52 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.